LIXT — Lixte Biotechnology Holdings Income Statement
0.000.00%
Last trade - 00:00- $3.36m
- $5.82m
Annual income statement for Lixte Biotechnology Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 3.27 | 6.72 | 6.31 | 5.09 | 3.57 |
| Operating Profit | -3.27 | -6.72 | -6.31 | -5.09 | -3.57 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -3.26 | -6.73 | -6.31 | -5.09 | -3.59 |
| Net Income After Taxes | -3.26 | -6.73 | -6.31 | -5.09 | -3.59 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.26 | -6.73 | -6.31 | -5.09 | -3.59 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.26 | -6.73 | -6.31 | -5.09 | -3.59 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.9 | -4.99 | -3.99 | -2.66 | -1.59 |